EUCTR2004-005169-39-SE进行中（未招募）不适用
A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study, subjects must fulfil all of the following criteria:
- •1.Subjects must have provided informed consent in writing for the participation in this study
- •2.Subjects aged 18 to 79 years inclusive, male or female
- •3.Subjects who seek medical advice in primary care for symptoms thought by the PCP to arise from the upper GI tract (any of those symptoms listed in Table 3)
- •4.The symptoms thought to pertain to the upper GI tract must have been present for at least 4 weeks prior to Visit 1 and to have occurred at least twice a week during that period
- •5.The symptoms thought to pertain to the upper GI tract must have been of at least mild severity for a minimum of 3 days during the week prior to Visit 1
- •6.Subjects judged to be capable to understand and to complete diaries and questionnaires reliably.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any of the following is regarded as a criterion for exclusion from the study:
- •1.Upper GI endoscopy performed within a year prior to Visit 1
- •2.Previous anti-reflux surgery, surgery for peptic ulcer or any form of upper gastrointestinal resective surgery
- •3.Contra-indication to the Bravo™ procedure such as subjects with a history of bleeding diathesis, strictures anywhere along the GI-tract, esophageal varices, obstructions, or subjects equipped with a pacemaker, an implantable cardiac defibrillator or an implantable neurostimulator (NB: subjects with LA Grade D confirmed by endoscopy at Visit 2 can continue the study without performing the Bravo™ procedure)
- •4.Any use of PPIs within 2 months prior to Visit 1, including those obtained OTC
- •5.Use of the following drug therapy within 4 weeks prior to Visit 1:
- •-Daily use of acetylsalicylic acid (ASA) at any dose greater than 165 mg
- •-Daily use of non-steroidal anti-inflammatory drugs (NSAIDs) including
- •COX-2 inhibitors at any dose
- •6.Presence of any alarm features, such as:
- •-Unintentional weight loss >3 kg in the previous 3 months
- •-Haematemesis, melaena or per-rectum blood loss in the previous year
- •-Progressive dysphagia
- •-Any other symptom suggestive of malignancy
- •7.Any significant past or current disease or disorder (e.g.; cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, malignant, or psychiatric), as revealed by history, physical examination or laboratory assessments, which, in the opinion of the investigator, may put the subject at risk, alter their performance or influence the subject’s ability to participate in the study
- •8.Unwillingness to undergo endoscopy, esophageal pH monitoring or to complete any other standard assessments used in the study
- •9.History of alcohol or drug abuse in the last two years or any condition associated with poor compliance, including expected non-cooperation, as judged by the investigator
- •10.Pregnancy or lactation. Women of childbearing potential must maintain effective contraception during the study period, as judged by the investigator
- •11.Treatment with phenytoin, warfarin (or other vitamin K antagonists), ketoconazole, itraconazole and cisapride
- •12.Planned donation of blood during the study period
- •13.Planned hospitalisation during the study period
- •14.Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
- •15.Treatment with any medicinal investigational product within 30 days prior to Visit 1 or within another time-frame according to local requirements, if applicable
- •16.Previous enrolment in the present study
- •17.Participation as a subject in any other medical research project during and in the 4 weeks prior to the start of the study
- •In addition to the above, the following criterion excludes the subject from participation into the study at Visit 2:
- •18.Any findings at endoscopy that make further participation in the study clinically inappropriate as judged by the investigator, such as suspected malignancy or evidence of clinically significant gastrointestinal bleeding (i.e. visible vessel or other stigmata of current bleeding) [NB: Subjects with macroscopic Barrett’s esophagus (defined as subjects with endoscopic indications of any columnar lined epithelium in the esophagus) are not to be excluded; Subjects with LA Grade D confirmed by endoscopy at Visit 2 can continue the study without performing the Bravo™ procedu
研究者
相似试验
进行中（未招募）
不适用
A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d.Symptoms from the upper gastrointestinal tractEUCTR2004-005169-39-GBAstraZeneca AB350
进行中（未招募）
不适用
A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d.EUCTR2004-005169-39-DKAstraZeneca AB350
进行中（未招募）
不适用
A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d.Symptoms from the upper gastrointestinal tractEUCTR2004-005169-39-DEAstraZeneca AB350
尚未招募
不适用
Prospectiv, single-center trial to evaluate the rate of of hypoxaemia and hypotension in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) with sedation.K83.0K76.9Liver disease, unspecifiedCholangitisDRKS00005201Interdisziplinäres Endoskopie ZentrumUniklinikum Heidelberg200
已完成
不适用
To compare the exposure levels of selected smoke constituents as determined by biomarkers of exposure, filter analysis, sensory perception and other parameters when smokers using commercial cigarettes are switched to novel cigarettesISRCTN72157335British American Tobacco (Investments) Ltd (UK)300